GlobeNewswire: Myriad Genetics, Inc. Contains the last 10 of 690 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T12:11:48ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/22/2850730/0/en/Myriad-Genetics-Announces-Foundational-Patent-Granted-for-Molecular-Residual-Disease-MRD-with-Early-Priority-Date.html?f=22&fvtc=4&fvtv=12695Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date2024-03-22T01:40:00Z<![CDATA[SALT LAKE CITY, March 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and Trademark Office has issued a patent that will strengthen its ability to deliver a tumor-informed, high-definition, molecular residual disease (MRD) assay to market.]]>https://www.globenewswire.com/news-release/2024/03/20/2849765/0/en/Myriad-Genetics-Announces-Patent-Granted-for-SneakPeek-Snap-Device.html?f=22&fvtc=4&fvtv=12695Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device2024-03-20T20:05:00Z<![CDATA[SALT LAKE CITY, March 20, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the U.S. Patent and Trademark Office has granted a patent that covers the use of push-button blood collection devices for PCR-based fetal sex determination.]]>https://www.globenewswire.com/news-release/2024/02/27/2836437/0/en/Myriad-Genetics-Reports-Strong-Fourth-Quarter-and-Full-Year-2023-Financial-Results-Fourth-Quarter-Revenue-of-197-Million-and-Full-Year-Revenue-of-753-Million-Each-Grew-11-Year-Over.html?f=22&fvtc=4&fvtv=12695Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance2024-02-27T21:05:00Z<![CDATA[Highlights:]]>https://www.globenewswire.com/news-release/2024/02/27/2836133/0/en/Myriad-Genetics-and-National-Cancer-Center-Hospital-East-in-Japan-Collaborate-on-Pan-Cancer-MRD-Monitoring-Clinical-Trial-SCRUM-MONSTAR-SCREEN-3.html?f=22&fvtc=4&fvtv=12695Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-32024-02-27T14:15:00Z<![CDATA[Myriad’s Precise MRD test will be used to evaluate the broad applicability of MRD testing across many cancer types Myriad’s Precise MRD test will be used to evaluate the broad applicability of MRD testing across many cancer types]]>https://www.globenewswire.com/news-release/2024/02/21/2833115/0/en/Myriad-Genetics-to-Release-Fourth-Quarter-and-Full-Year-2023-Financial-Results-on-February-27-2024.html?f=22&fvtc=4&fvtv=12695Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 20242024-02-21T21:05:00Z<![CDATA[Management will also participate in two upcoming healthcare conferences Management will also participate in two upcoming healthcare conferences]]>https://www.globenewswire.com/news-release/2024/02/15/2830362/0/en/Myriad-Genetics-Appoints-Dallas-Reed-MD-FACOG-FACMG-as-Principal-Medical-Advisor-of-Women-s-Health.html?f=22&fvtc=4&fvtv=12695Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health2024-02-15T21:05:00Z<![CDATA[SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor to its women’s health business unit, effective immediately.]]>Myriad Genetics, Inc. today announced the appointment of Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor to its women’s health business unit, effective immediately.Dr. Dallas Reedhttps://www.globenewswire.com/news-release/2024/02/01/2822099/0/en/Myriad-Genetics-Completes-Acquisition-of-Precise-Tumor-Precise-Liquid-and-Laboratory-from-Intermountain-Precision-Genomics.html?f=22&fvtc=4&fvtv=12695Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics2024-02-01T14:25:00Z<![CDATA[SALT LAKE CITY, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has completed the acquisition from Intermountain Health of select assets from its Intermountain Precision Genomics (IPG) laboratory business, including the Precise™ Tumor Test, the Precise Liquid Test, and IPG’s CLIA-certified laboratory in St. George, Utah.]]>https://www.globenewswire.com/news-release/2024/01/30/2820540/0/en/Myriad-Genetics-Names-George-Daneker-Jr-MD-as-President-and-Chief-Clinical-Officer-of-Oncology.html?f=22&fvtc=4&fvtv=12695Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology2024-01-30T22:00:00Z<![CDATA[SALT LAKE CITY, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology, effective March 18, 2024.]]>https://www.globenewswire.com/news-release/2024/01/18/2812030/0/en/Myriad-Genetics-to-Acquire-Precise-Tumor-Precise-Liquid-and-Laboratory-from-Intermountain-Precision-Genomics.html?f=22&fvtc=4&fvtv=12695Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics2024-01-18T23:10:00Z<![CDATA[SALT LAKE CITY, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has entered into a definitive agreement to acquire select assets from Intermountain Precision Genomics’ (IPG) laboratory business, including the Precise™ Tumor Test, the Precise Liquid Test, and IPG’s CLIA-certified laboratory in St. George, Utah where the Precise Tumor Test is currently performed.]]>https://www.globenewswire.com/news-release/2024/01/09/2806671/0/en/Myriad-Genetics-Applauds-New-Germline-Testing-Guideline-for-Patients-with-Breast-Cancer-from-ASCO-SSO.html?f=22&fvtc=4&fvtv=12695Myriad Genetics Applauds New Germline Testing Guideline for Patients with Breast Cancer from ASCO-SSO2024-01-09T21:05:00Z<![CDATA[SALT LAKE CITY, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced its support for the American Society of Clinical Oncology (ASCO)—Society of Surgical Oncology (SSO) guideline for germline testing in patients with breast cancer.]]>